Cargando…

Immunity and AAV-Mediated Gene Therapy for Muscular Dystrophies in Large Animal Models and Human Trials

Adeno-associated viral (AAV) vector-mediated gene replacement for the treatment of muscular dystrophy represents a promising therapeutic strategy in modern medicine. One major obstacle in using AAV vectors for in vivo gene delivery is the development of host immune responses to the viral capsid prot...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Zejing, Tapscott, Stephen J., Chamberlain, Jeffrey S., Storb, Rainer
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Research Foundation 2011
Materias:	Microbiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3180173/ https://www.ncbi.nlm.nih.gov/pubmed/21980317 http://dx.doi.org/10.3389/fmicb.2011.00201

Ejemplares similares

Immune Responses to rAAV6: The Influence of Canine Parvovirus Vaccination and Neonatal Administration of Viral Vector
por: Arnett, Andrea L. H., et al.
Publicado: (2011)

Elimination of contaminating cap genes in AAV vector virions reduces immune responses and improves transgene expression in a canine gene therapy model
por: Wang, Zejing, et al.
Publicado: (2014)

Innate and adaptive AAV-mediated immune responses in a mouse model of Duchenne muscular dystrophy
por: Emami, Michael R., et al.
Publicado: (2023)

Multi-Parametric MRI at 14T for Muscular Dystrophy Mice Treated with AAV Vector-Mediated Gene Therapy
por: Park, Joshua, et al.
Publicado: (2015)

Animal Models for Muscular Dystrophy Show Different Patterns of Sarcolemmal Disruption
por: Straub, Volker, et al.
Publicado: (1997)

Systemic AAV Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy
por: Duan, Dongsheng
Publicado: (2018)

AAV6-mediated Systemic shRNA Delivery Reverses Disease in a Mouse Model of Facioscapulohumeral Muscular Dystrophy
por: Bortolanza, Sergia, et al.
Publicado: (2011)

Current Challenges and Future Directions in Recombinant AAV-Mediated Gene Therapy of Duchenne Muscular Dystrophy
por: Okada, Takashi, et al.
Publicado: (2013)

Adeno-Associated Virus (AAV)-Mediated Gene Therapy for Duchenne Muscular Dystrophy: The Issue of Transgene Persistence
por: Manini, Arianna, et al.
Publicado: (2022)

Strategies for Bottlenecks of rAAV-Mediated Expression in Skeletal and Cardiac Muscle of Duchenne Muscular Dystrophy
por: Li, Na, et al.
Publicado: (2022)

Immunohistochemical Characterization of FacioscapulohumeralMuscular Dystrophy Muscle Biopsies
por: Statland, Jeffrey M., et al.
Publicado: (2015)

Long-term Evaluation of AAV-CRISPR Genome Editing for Duchenne Muscular Dystrophy
por: Nelson, Christopher E., et al.
Publicado: (2019)

Assessment of Therapeutic Potential of a Dual AAV Approach for Duchenne Muscular Dystrophy
por: Albini, Sonia, et al.
Publicado: (2023)

Hematopoietic Cell Transplantation Provides an Immune-tolerant Platform for Myoblast Transplantation in Dystrophic Dogs
por: Parker, Maura H, et al.
Publicado: (2008)

Muscular Dystrophy Meets the Gene Chip: New Insights into Disease Pathogenesis
por: Chamberlain, Jeffrey S.
Publicado: (2000)

Changes in Myonuclear Number During Postnatal Growth – Implications for AAV Gene Therapy for Muscular Dystrophy
por: Morgan, Jennifer, et al.
Publicado: (2021)

A feedback loop between nonsense-mediated decay and the retrogene DUX4 in facioscapulohumeral muscular dystrophy
por: Feng, Qing, et al.
Publicado: (2015)

Adapting MRI as a clinical outcome measure for a facioscapulohumeral muscular dystrophy trial of prednisone and tacrolimus: case report
por: Wang, Leo H., et al.
Publicado: (2021)

Innate Immune Responses to AAV Vectors
por: Rogers, Geoffrey L., et al.
Publicado: (2011)

Longitudinal study of MRI and functional outcome measures in facioscapulohumeral muscular dystrophy
por: Wang, Leo H., et al.
Publicado: (2021)

Cellular and animal models for facioscapulohumeral muscular dystrophy
por: DeSimone, Alec M., et al.
Publicado: (2020)

Disease Rescue and Increased Lifespan in a Model of Cardiomyopathy and Muscular Dystrophy by Combined AAV Treatments
por: Vitiello, Carmen, et al.
Publicado: (2009)

Amelioration of Muscle and Nerve Pathology in LAMA2 Muscular Dystrophy by AAV9-Mini-Agrin
por: Qiao, Chunping, et al.
Publicado: (2018)

BB-301: a silence and replace AAV-based vector for the treatment of oculopharyngeal muscular dystrophy
por: Strings-Ufombah, Vanessa, et al.
Publicado: (2021)

Evaluation of an AAV9-mini-dystrophin gene therapy candidate in a rat model of Duchenne muscular dystrophy
por: Le Guiner, Caroline, et al.
Publicado: (2023)

The immune system in Duchenne muscular dystrophy: Friend or foe
por: Villalta, S Armando, et al.
Publicado: (2015)

Quantitative proteomics reveals key roles for post-transcriptional gene regulation in the molecular pathology of facioscapulohumeral muscular dystrophy
por: Jagannathan, Sujatha, et al.
Publicado: (2019)

Genetic Engineering of Dystroglycan in Animal Models of Muscular Dystrophy
por: Sciandra, Francesca, et al.
Publicado: (2015)

CRISPR-Generated Animal Models of Duchenne Muscular Dystrophy
por: Lim, Kenji Rowel Q., et al.
Publicado: (2020)

Microdystrophin Expression as a Surrogate Endpoint for Duchenne Muscular Dystrophy Clinical Trials
por: Chamberlain, Jeffrey S., et al.
Publicado: (2023)

A consolidated AAV system for single-cut CRISPR correction of a common Duchenne muscular dystrophy mutation
por: Zhang, Yu, et al.
Publicado: (2021)

Expression and function of four AAV-based constructs for dystrophin restoration in the mdx mouse model of Duchenne muscular dystrophy
por: Potter, Rachael A., et al.
Publicado: (2023)

Tracking progress: an update on animal models for Duchenne muscular dystrophy
por: Wells, Dominic J.
Publicado: (2018)

Muscular dystrophy: Experimental animal models and therapeutic approaches (Review)
por: Gaina, Gisela, et al.
Publicado: (2021)

T Cell-Mediated Immune Responses to AAV and AAV Vectors
por: Ertl, Hildegund C. J.
Publicado: (2021)

DUX4 promotes transcription of FRG2 by directly activating its promoter in facioscapulohumeral muscular dystrophy
por: Thijssen, Peter E, et al.
Publicado: (2014)

Gene Therapy Rescues Cardiac Dysfunction in Duchenne Muscular Dystrophy Mice by Elevating Cardiomyocyte Deoxy-Adenosine Triphosphate
por: Kolwicz, Stephen C., et al.
Publicado: (2019)

Evaluation of blood gene expression levels in facioscapulohumeral muscular dystrophy patients
por: Signorelli, M., et al.
Publicado: (2020)

The Immune System in Duchenne Muscular Dystrophy Pathogenesis
por: Tripodi, Luana, et al.
Publicado: (2021)

Animal models of Duchenne muscular dystrophy: from basic mechanisms to gene therapy
por: McGreevy, Joe W., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_c1fffh85i1tho0koh0e3vtgg9c